Trump Administration Restricts Federal Funding for Transgender Healthcare for Minors
The Trump administration announced a new rule that stops federal funding for transgender healthcare for minors. This rule was issued by the Centers for Medicare and Medicaid Services (CMS). It prevents Medicaid dollars from being used for “sex-rejecting procedures” for those under 18. It also restricts the Children’s Health Insurance Program (CHIP) from funding these procedures for anyone under 19.
Current beneficiaries of cross-sex hormone therapy can continue their benefits for six months after the rule takes effect. The effective date is expected to be October 12, 2026. President Trump publicly stated that these procedures cause irreversible harm to children.
Criticism from advocacy groups was swift. Human Rights Campaign President Kelley Robinson accused the administration of targeting trans youth and their families. Rodrigo Heng-Lehtinen from The Trevor Project called the rule a “dangerous restriction on doctor-prescribed health care.” Research shows that less than one percent of transgender minors receive surgical gender-affirming care before adulthood. Cisgender male minors more frequently undergo these surgeries.
In related healthcare policy news, Sen. John Cornyn of Texas highlighted the role of vaccines in preventing millions of deaths since 1974. He connected this to President Trump’s executive order to change the standard order of childhood vaccinations. This includes splitting up the MMR shots for mumps, measles, and rubella.
The company Hims & Hers Health announced plans to sell compounded peptides. CEO Andrew Dudum outlined a development plan for a new peptides experience involving U.S. manufacturing, clinical-led guidance, and regular blood testing.
In Texas, Attorney General Ken Paxton intervened in a surrogacy case concerning a fetus with a heart defect. The unborn child, called “baby Gabriel,” has hypoplastic left heart syndrome, requiring medical attention.
Further healthcare updates include ongoing vaccination policies in Texas, changes in Massachusetts abortion laws, and conflicts over vaccine industry roles in policy. The administration’s recent decisions continue to elicit strong reactions across various sectors.